Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Teen First In Indiana To Receive New Cancer Treatment

Kylee Sweat is Riley Hospital’s first ever CAR T patient and the first pediatric patient to start treatment in Indiana.
Photo courtesy of IU Riley Hospital
Kylee Sweat is Riley Hospital’s first ever CAR T patient and the first pediatric patient to start treatment in Indiana.

An Indiana teenager is the first in the state to receive a new type of cancer treatment for leukemia. CAR T cell therapy was just approved by the FDA last year. 

The treatment is a type of immunotherapy where a patient’s T cells are taken from their body and re-engineered to fight their cancer.  The therapy has been approved for use against leukemia and lymphoma.  

Eighteen-year-old Kylee Sweat relapsed from acute lymphoblastic leukemia or ALL, three times. IU Riley Hospital Dr. Jodi Skiles says in trials the new treatment is effective in more than 80 percent of pediatric ALL cases. 

"Which is unheard of when you are talking about dealing with patients with multiple relapse disease that didn’t respond to standard chemo upfront," says Skiles. 

CAR T cell therapy has fewer side effects and less long-term toxicity.  Kylee’s T cells have been sent to a drug company that will re-engineer them. 

Skiles says CAR T is known as the “living drug.” 

"The really cool thing is that when the cells are re-infused into the patient, the goal, is that not only would those cells attack existing leukemia cells but those cells would also receive a message from the patient’s body to expand and multiply," says Skiles. 

The cells will be transferred back into her body in the coming weeks.  

Jill Sheridan Poulos is the managing city editor at WFYI. She was previously a member of the IPB News teams covering health and science, and at WFYI as a reporter and anchor.
Support independent journalism today. You rely on WFYI to stay informed, and we depend on you to make our work possible. Donate to power our nonprofit reporting today. Give now.